Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Imatinib can cause hair loss due to lichen planopilaris.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Ritlecitinib was generally well tolerated in children with alopecia areata.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Tadalafil and Finasteride may help treat aggressive melanoma.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.